Browse the evidence

In Type 2 Diabetes, the adoption of newer glucose-lowering medications (GLP-1 agonists and SGLT2 inhibitors) is associated with a significant decline in fracture incidence rates, particularly in men and women under 50 and over 70.

If you have Type 2 Diabetes, discuss with your doctor whether your current medication increases your fracture risk. The data suggests that switching to newer classes of drugs, specifically GLP-1 agonists or SGLT2 inhibitors, is associated with a significant reduction in fracture rates compared to older medications like sulfonylureas.

GLP-1 receptor agonists (specifically liraglutide and semaglutide) improve histological features of NASH and achieve resolution of NASH without worsening fibrosis in adults with or without type 2 diabetes.

If you have NASH, GLP-1 agonists like semaglutide or liraglutide are proven to improve liver health, potentially resolving the disease without worsening scarring. They are taken as injections (daily or weekly). While they can cause nausea, the liver benefits are substantial, especially if you have type 2 diabetes or obesity. Consult your doctor for dosing.

SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce liver fat content in patients with NAFLD, as assessed by MRI-based techniques.

SGLT2 inhibitors like empagliflozin or dapagliflozin reduce liver fat in people with type 2 diabetes and fatty liver. They are oral medications taken daily. They can increase the risk of genital infections, so good hygiene is important. They also help with weight and blood sugar.

Physical exercise provides cardiovascular and mental health benefits independent of weight loss, justifying its inclusion in obesity treatment even when pharmacological weight loss is significant.

Even if your medication helps you lose weight, keep exercising. It protects your heart and mood in ways that weight loss alone might not. Focus on brisk walking and basic strength exercises rather than intense workouts.

Gastric bypass results in large and long-lasting weight loss (25-27% total body weight loss at 12-15 years) and remission of obesity-related conditions, making it suitable for patients with BMI 35-50 kg/m2, especially with type 2 diabetes or reflux.

Gastric bypass is a highly effective surgical option for patients with BMI 35-50, especially those with type 2 diabetes or reflux. It leads to large, long-lasting weight loss (25-27% at 12-15 years) and remission of obesity-related conditions.

Tirzepatide (15 mg) produces a greater improvement in insulin sensitivity per unit of weight loss compared to semaglutide (1 mg) in patients with type 2 diabetes, suggesting mechanisms beyond simple adiposity reduction.

If you are treating type 2 diabetes with GLP-1 based therapies, tirzepatide (15 mg) appears to offer superior improvements in how your body uses insulin for every pound lost, compared to semaglutide (1 mg). This suggests tirzepatide works through additional hormonal pathways (GIP/GLP-1) beyond just reducing fat mass. For patients prioritizing metabolic health improvements alongside weight loss, this distinction may be clinically relevant.

GLP-1 receptor agonists (e.g., Liraglutide) reduce appetite and improve glucose tolerance by stimulating anorexigenic POMC/CART neurons and suppressing orexigenic AgRP/NPY neurons via cAMP and GABA-dependent signaling pathways.

GLP-1 based therapies work by targeting the brain's hunger centers (POMC/CART) to reduce appetite and improve blood sugar control. This suggests that obesity management can involve pharmacological support of natural hormonal signals, rather than relying solely on behavioral changes.

Testosterone therapy in transgender men leads to increased lean mass and visceral adiposity, while estrogen therapy in transgender women leads to decreased lean mass and increased fat mass, confirming the causal role of sex steroids in body composition.

If you are undergoing gender-affirming hormone therapy, expect your body composition to shift towards your new hormonal profile. Trans men will likely gain muscle and visceral fat; trans women will likely lose muscle and gain subcutaneous fat. This is a direct result of the hormones, not lifestyle failure.

Menopause triggers a shift in fat distribution from protective subcutaneous tissue to harmful visceral adipose tissue due to declining estrogen levels, increasing the risk of metabolic disease.

As you approach menopause, your body will naturally start storing more fat around your organs (visceral) rather than your hips and thighs. This increases metabolic risk. Hormone replacement therapy can partially reverse this shift, but lifestyle management of visceral fat becomes critical.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is bidirectionally associated with the development and progression of cardiovascular, renal, and metabolic disorders, acting as both a driver and consequence of systemic cardiometabolic dysfunction.

If you have fatty liver (MASLD), it is not just a liver issue; it significantly increases your risk for heart disease, kidney disease, and diabetes. You need to manage your metabolic health (weight, blood sugar, blood pressure) comprehensively to protect your heart and kidneys, not just your liver.

SGLT2 inhibitors, GLP-1 receptor agonists, and finerenone demonstrate benefits across multiple cardiometabolic conditions, improving clinical outcomes in patients with MASLD, CKD, and CVD.

Current medications like SGLT2 inhibitors, GLP-1 agonists, and finerenone are effective for treating multiple aspects of cardiometabolic disease simultaneously. Discuss these options with your doctor if you have liver, kidney, or heart issues.

Tirzepatide (5-15 mg once weekly) significantly reduces the risk of composite kidney endpoints (eGFR decline ≥40%, renal death, kidney failure, or new-onset macroalbuminuria) in patients with type 2 diabetes and high cardiovascular risk compared to insulin glargine.

If you have type 2 diabetes and are at high risk for heart or kidney problems, tirzepatide (a once-weekly injection) has been shown to significantly reduce the risk of serious kidney issues compared to insulin glargine. This benefit includes slowing the decline in kidney function and preventing the onset of severe protein in the urine. While there may be an initial, reversible drop in kidney function numbers, this is a sign of reduced stress on the kidneys. Always consult your doctor to see if this treatment is appropriate for your specific health profile.

BCAA supplementation activates anabolic signaling pathways (mTORC1) and improves hormonal profiles (testosterone/cortisol ratio) in the short term, but this does not translate to long-term muscle or strength gains if total protein intake is adequate.

BCAAs do trigger muscle-building signals in your body, but this doesn't mean you will gain muscle or strength. If you are eating enough protein from food, BCAAs add no value. Do not use them to try to 'boost' your muscle growth.

Time-restricted eating (TRE) improves metabolic health markers (insulin sensitivity, glucose control) independent of weight loss when the eating window is aligned with circadian rhythms (early/mid-TRE), whereas late or self-selected windows show little to no benefit.

If you want to try Time-Restricted Eating, start by shifting your eating window to the earlier part of the day (e.g., 8am to 4pm or 10am to 6pm) rather than skipping breakfast or eating late at night. Keep your food choices normal (ad libitum) but ensure you finish eating before 8pm. This alignment with your body's natural circadian rhythms is what drives metabolic improvements, independent of weight loss.

Liraglutide improves insulin sensitivity (measured by HOMA-IR, HOMA2, and Matsuda index) rapidly, within 2 weeks, independent of weight loss.

If you have obesity and prediabetes, liraglutide improves how your body handles insulin within two weeks, even before you lose significant weight. This is a direct drug effect, not just a result of dieting.

Fasting induces a metabolic switch from glycogenolysis to gluconeogenesis, lipolysis, and ketogenesis, which is considered a main driver of the metabolic health benefits provided by IF.

During fasting, your body switches from burning sugar to burning fat and producing ketones. This metabolic shift is likely why fasting can be healthy, even if it doesn't always lead to more weight loss than just eating less.

Obesity and Type 2 Diabetes are associated with altered secretion patterns of enteroendocrine hormones, specifically decreased GLP-1 and PYY, and increased ghrelin.

In obesity and diabetes, your gut's natural hormone signals are often disrupted, with less 'satiety' hormone (GLP-1) and more 'hunger' hormone (ghrelin). This contributes to the difficulty in managing weight.

Fructose consumption, particularly in large amounts or from added sugars, stimulates hepatic de novo lipogenesis and VLDL-triglyceride secretion, increasing intrahepatic fat and cardiovascular risk, whereas glucose and starch have different, often less adverse, metabolic profiles.

Limit added sugars, particularly those high in fructose (like HFCS and sucrose), as they can promote liver fat accumulation and high triglycerides. While whole fruits are healthy due to fiber, be mindful of concentrated fructose sources. Physical activity can mitigate some of these effects by increasing fructose oxidation.

GLP-1 RAs reduce blood pressure and albuminuria in patients with CKD and overweight/obesity, contributing to kidney and cardiovascular protection.

GLP-1 RAs can help lower your blood pressure and reduce protein in your urine (albuminuria), which are important markers for kidney and heart health. This benefit is partly due to weight loss but also direct effects of the medication.

Gut hormones (GLP-1, GIP, CCK, PYY, OXM) regulate food intake and energy homeostasis by acting on the hypothalamus and brainstem via direct circulation or vagus nerve signaling, while ghrelin stimulates appetite.

Understanding that gut hormones like GLP-1 and GIP signal satiety to the brain helps explain why medications mimicking these hormones (like semaglutide and tirzepatide) are effective for weight loss. Conversely, ghrelin signals hunger. This biological basis supports the use of drugs that target these pathways.

NNC9204-1177, a glucagon/GLP-1 receptor co-agonist, produces dose-dependent, clinically relevant weight loss (up to 12.6%) in adults with overweight or obesity, but its clinical development was halted due to unexpected safety signals including increased heart rate, impaired glucose tolerance, and elevated inflammatory markers.

NNC9204-1177 is not available for clinical use because it caused unacceptable side effects like rapid heart rate and inflammation, despite causing significant weight loss. Do not seek this specific compound. However, the mechanism (glucagon/GLP-1 co-agonism) suggests that combining these pathways can be more effective for weight loss than GLP-1 alone, provided safety is managed. Current approved GLP-1 agonists (like semaglutide) do not have this glucagon component and thus avoid this specific safety profile.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce liver fat content and improve histological markers of NASH (resolution without fibrosis worsening) in patients with NAFLD, with efficacy demonstrated across liraglutide, semaglutide, and tirzepatide.

If you have fatty liver disease (NAFLD) or NASH, GLP-1 medications like liraglutide, semaglutide, or tirzepatide are proven to reduce liver fat and improve liver health, often more effectively than placebo. These drugs work through hormonal mechanisms that reduce liver fat independently of weight loss in some cases. While gastrointestinal side effects like nausea are common, they are often manageable. Consult a doctor to see if you are a candidate, especially if you also have Type 2 Diabetes or obesity.

The combination of bupropion and naltrexone reduces body weight by stimulating POMC neurons to decrease energy intake and increase expenditure, with naltrexone blocking negative feedback to enhance this effect.

Bupropion/naltrexone is a combination pill that helps reduce appetite and increase energy expenditure by acting on brain pathways. It is effective for weight loss in people with obesity and comorbidities like hypertension or diabetes. However, it is not suitable for everyone, particularly those with a history of seizures or eating disorders. Consult your doctor to determine if it is safe for you.

Female sex is significantly associated with a hyper-response (>15% total body weight loss) to subcutaneous GLP-1 analogue therapy compared to non-response, whereas male sex is not.

If you are a woman taking a GLP-1 medication like semaglutide or liraglutide for obesity, you are statistically more likely to achieve significant weight loss (hyper-response) than a man taking the same medication. This is likely due to physiological differences in how your body processes the drug and regulates appetite hormones. Men may need higher doses to achieve similar results. If you are not losing weight, discuss dose adjustment or alternative treatments with your doctor rather than stopping abruptly.